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Abstract
Background: Ollier disease is a rare, non-hereditary disorder which is characterized by the presence of multiple
enchondromas (ECs), benign cartilaginous neoplasms arising within the medulla of the bone, with an asymmetric
distribution. The risk of malignant transformation towards central chondrosarcoma (CS) is increased up to 35%. The
aetiology of Ollier disease is unknown.
Methods: We undertook genome-wide copy number and loss of heterozygosity (LOH) analysis using Affymetrix
SNP 6.0 array on 37 tumours of 28 Ollier patients in combination with expression array using Illumina BeadArray
v3.0 for 7 ECs of 6 patients.
Results: Non-recurrent EC specific copy number alterations were found at FAM86D, PRKG1 and ANKS1B. LOH with
copy number loss of chromosome 6 was found in two ECs from two unrelated Ollier patients. One of these
patients also had LOH at chromosome 3. However, no common genomic alterations were found for all ECs. Using
an integration approach of SNP and expression array we identified loss as well as down regulation of POU5F1 and
gain as well as up regulation of NIPBL. None of these candidate regions were affected in more than two Ollier
patients suggesting these changes to be random secondary events in EC development. An increased number of
genetic alterations and LOH were found in Ollier CS which mainly involves chromosomes 9p, 6q, 5q and 3p.
Conclusions: We present the first genome-wide analysis of the largest international series of Ollier ECs and CS
reported so far and demonstrate that copy number alterations and LOH are rare and non-recurrent in Ollier ECs
while secondary CS are genetically unstable. One could predict that instead small deletions, point mutations or
epigenetic mechanisms play a role in the origin of ECs of Ollier disease.
Background
Enchondroma (EC), a benign cartilage forming tumor in
the medulla of the bone, is thought to be a precursor of
secondary central chondrosarcoma (CS). EC develops
either as a single, solitary lesion or as multiple lesions in
the context of Ollier disease [1]. Ollier disease is the
most common subtype of enchondromatosis and shows
multiple ECs with marked unilateral predominance
[1,2]. The risk of malignant transformation towards cen-
tral CS is up to 35% in Ollier disease [1,3]. There is no
marker that would indicate progression towards malig-
nancy, thus there is a vital need to understand the
genetics of these tumors which may help to develop
markers for early diagnosis. A comprehensive under-
standing of the molecular events in ECs and central CS
also enables the identification of possible targets for
treatment [4].
While the genetics of enchondroma is poorly under-
stood, the involvement of the EXT genes is well estab-
lished in the development of solitary as well as
hereditary multiple osteochondromas (MO) (OMIM
133700), benign cartilage tumors at the surface of bone
[5]. The lack of EXT function seems to disturb hedge-
hog signalling in MO, while activated hedgehog signal-
ling in mice seems to underlie the development of the
Ollier related phenotype [4]. Heterozygous mutations in
PTH1R are found in a small subset of Ollier patients
[6-8]. It is however unclear whether these mutations in
PTH1R are causing or modifying the disease [7], and
since ~90% of Ollier patients lack PTH1R mutations, we
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changes using genomic arrays.
We hypothesized Ollier disease to be a germ-line
mosaic condition due to the fact that it is non-heredi-
tary and because of its unilateral predominance feature
[3,9]. An early postzygotic mutation resulting in asym-
metric involvement of skeletal structures can be
expected, as was also shown for polyostotic fibrous dys-
plasia [10]. One could speculate that an inactivating
mutation in a tumor suppressor gene, similar to EXTs
in osteochondroma, would have occurred in the devel-
oping mesoderm early after gastrulation. In case of a
tumor suppressor gene, later on, an additional hit may
be required for the formation of ECs with subsequent
genetic changes causing progression towards central CS.
We tested this hypothesis using high-resolution SNP
array combined with expression array on DNA derived
from tumor tissue and, whenever available, normal
DNA from Ollier patients.
SNP arrays provide an excellent possibility for large-
scale, genome-wide, high-resolution analysis of both
DNA copy number alterations (CNA) and loss of het-
erozygosity (LOH) in cancer cells. It also provides a fea-
sible means of detecting genotyping alterations in the
tumors of individual patients and, in principle enables
the identification of new areas with common allelic
imbalance that could harbor potential tumor suppressor
genes which helps in the identification of novel candi-
date genes affected by genomic abnormalities [11,12]. In
the present study, we used Affymetrix Genome-Wide
Human SNP Array 6.0 to obtain a comprehensive regis-
try of genetic aberrations in 37 tumors of 28 patients
with Ollier disease and correlate it with gene expression
using Illumina Human-6 v3 Expression Array and qRT-
PCR and protein expression using tissue microarray
(TMA). Based on the obtained genomic profiles with
limited and non-recurrent genetic changes in Ollier
ECs, we conclude that they are genetically heteroge-
neous and that the reported CNA in this study are likely
to be secondary random events in ECs.
Materials and methods
Patient materials and reference samples
Fresh frozen tissues from 37 tumors from 28 patients
diagnosed with Ollier disease were collected from the
E u r o B o N e tc o n s o r t i u m( h ttp://www.eurobonet.eu)
(Table 1): Leiden University Medical Center, The Neth-
erlands (12 tumors), Leuven University, Belgium (5
tumors), Rizzoli Institute, Italy (6 tumors), Royal Ortho-
paedic Hospital, United Kingdom (7 tumors), Lund Uni-
versity, Sweden (2 tumors), Netherlands Committee on
Bone Tumors, The Netherlands (2 tumors), Heidelberg
University, Germany (1 tumor), University of Ghent,
Belgium (1 tumor) and Groningen University Medical
Center, The Netherlands (1 tumor). All samples were
derived from primary tumors, not from recurrent
tumors, and all were graded according to Evans et al
[13]. Diagnoses were originally made in the multidisci-
plinary teams of the centers of origin. The histology was
revised and representativity was assessed on the avail-
able paraffin or frozen tissue by one experienced bone
tumor pathologist. For SNP array analysis, 14 Ollier
ECs, and 23 Ollier CS (13 grade I, 8 grade II, 2 grade
III) from 28 Ollier patients were used. As controls,
normal DNA derived from fresh frozen muscle tissue
Table 1 Clinicopathological data of the Ollier patients
Patient
ID
Sample Tumor
Grade
Tumor
location
Gender Age Application
17 L1083 CS I metacarpal M 48 1,3
17 L2218 CS I phalanx M 49 1,3
20 L286* CS II femur F 23 1,3
21 L204* CS I femur M 26 1,3
21 L253* CS I tibia M 26 1,3
22 L206 EC phalanx F 26 1,2,3,4
22 L910 EC phalanx F 16 1,2,3,4
23 L813 CS II humerus M 68 1,3
25 L1251* EC phalanx M 15 1,2,3,4
25 L2220* EC metacarpal M 14 1,3,4
26 L1974 CS II scapula M 48 1,3
27 L1975* CS II femur M 31 1,3
28 L1976* CS II tibia M 41 1,3
29 L1977* CS I tibia M 41 1,3
29 L1978* EC foot M 38 1,3
30 L1980 CS II knee F 63 1,3
31 L810 CS III unknown M - 1,3
33 L1685 CS I pubic bone F 23 1,3
34 L1687 CS I phalanx M 18 1,3
34 L1686 EC phalanx M 18 1,2,3,4
35 L2386 CS I phalanx F 13 1,3
36 L2463* EC tibia F 12 1,3
38 L1629 EC unknown M 36 1,3
38 L1630 EC Iliac bone M 36 1,2,3,4
42 L2098 CS II humerus F 15 1,3
43 L2099 CS II humerus F 49 1,3
47 L2103a EC phalanx M 39 1,2,3,4
47 L2103b CS I phalanx M 39 1,3
48 L2104a CS III tibia M 35 1,3
48 L2104b EC femur M 35 1,3
50 L2221* CS I femur F 42 1,3
52 L1513* CS I femur F 23 1,3
54 L1490* EC phalanx F 12 1,3
61 L2205 EC ilium M 6 1,3
64 L1683 EC metacarpal F 29 1,2,3,4
68 L2280* CS I acromion F 24 1,3
69 L2513 CS I pelvis M 33 1,3
* Normal DNA available enabling paired analysis. Application - 1: sample used
for SNP array, 2: expression array, 3: MLPA and 4: qRT-PCR.
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(n = 4) was available for 11 Ollier patients and 3 patients
with unrelated bone diseases. We used blood lymphocyte
DNA from 12 healthy controls and 1 HapMap sample.
We also isolated DNA from saliva for 3 of these controls
to validate the use of saliva DNA in this study. Twenty
eight of these thirty controls and DNA from 10 addi-
tional HapMap samples were used in MLPA. RNA from
4 articular cartilage, 2 growth plates and 7 ECs was used
for expression array and 3 articular cartilage, 2 growth
plates and 8 ECs were used in qRT-PCR.
Five tissue micro array (TMA) blocks containing
86 tumors were constructed, of which 65 were Ollier
related and 21 were solitary central tumors (ECs and
C S )f r o mb o t ht h eE u r o B o N e ta n dt h eE u r o p e a nM u s -
culoskeletal Oncology Society (EMSOS) networks
(Table S1, Additional file 1): Leiden University Medical
Center, The Netherlands (27 tumors), Rizzoli Institute,
Italy (12 tumors), Copenhagen University, Denmark
(9 tumors), University clinic of Orthopaedic Surgery
and Medical university of Graz University, Austria
(6 tumors), Bern University, Switzerland (5 tumors),
University of Navarra, Spain (4 tumors), Netherlands
Committee on Bone Tumors (21 tumors), Istanbul
U n i v e r s i t y ,T u r k e y( 2t u m o r s ) .A l lt h es a m p l e sw e r e
obtained according to the ethical guidelines of the host
institution. Samples were coded and all procedures
were performed according to the ethical guidelines
“Code for Proper Secondary Use of Human Tissue in
The Netherlands” (Dutch Federation of Medical Scien-
tific Societies).
DNA and RNA isolation
Tumor samples were selected that contained more than
80% of tumor cells, as estimated on haematoxylin and
eosin-stained frozen sections. Most of the samples were
macro dissected and L2099 sample was micro dissected
to enrich the tumor percentage [14]. DNA from fresh
frozen tissue was isolated using the wizard genomic
DNA purification kit (Promega, Madison, WI), accord-
ing to the manufacturer instructions. Blood DNA was
isolated as described by Miller et al [15]. Saliva DNA
was isolated using the Oragene DNA kit (DNA Genotek
Inc Ontario, Canada) according to the protocol provided
by the supplier and DNA was precipitated using sodium
acetate precipitation. DNA concentration was quantified
spectrophotometrically using Nanodrop ND-1000
(Thermo Fisher Scientific, Waltham, MA, USA) and the
fragment sizes were determined on 1% agarose gel.
RNA isolation from the fresh frozen tissue was per-
formed as described previously [16]. RNA concentration
was measured spectrophotometrically and the fragment
sizes were determined by RNA 6000 Nano LabChip kit
using Agilent 2100 Bioanalyzer (Santa Clara, CA, USA).
DNA and RNA from all the samples were good enough
to continue with the experiment.
SNP Array and Data Analysis
We used the Affymetrix Genome-Wide Human SNP
Array 6.0. Genomic DNA preparation, labeling and
hybridization were performed according to Affymetrix’s
recommended protocols (Affymetrix, Santa Clara, CA,
USA). Then, arrays were scanned with GeneChip™
GSC3000 7G Whole-Genome Association System (Affy-
metrix). Overall hybridization quality was estimated by
the genotype call rate using the Birdseed genotype call-
ing algorithm in Genotyping Console (version 3.0.2,
Affymetrix). Average call rate was 97.83%. To analyze
the data we used statistical language R version 2.8 and
Nexus software version 4.1 (BioDiscovery, CA, USA).
We did not use HapMap samples as baseline in this
study to avoid the bias for the experiment performance
at different labs, batch effect and hybridization quality.
The analysis was performed on a subset (30 controls, 14
ECs and 23 CS of Ollier patients, Table 1) of a larger
experiment of 92 samples including samples unrelated
to Ollier disease to achieve a larger set of common con-
trols. Than we performed copy number analysis using
92 samples as a baseline in R software and only 29 con-
trol samples of high quality as a baseline in Nexus soft-
ware. Results that we obtained using different softwares
and different baselines were comparable. We used CEL
files in R software. For the genomic analysis using R, we
did genotyping using the CRLMM algorithm in the
Oligo package [17], copy number analysis using the
aroma affymetrix package [18], and we constructed
LAIR plots to visualize regions of LOH and allelic
imbalance [19]. Chromosome-X was not analyzed to
avoid gender-related issues [20]. In Nexus, we per-
formed copy number analysis using CNCHP log-ratio
files generated by genotyping console using 29 controls
as a baseline. Hidden Markov model (HMM) based
SNP-FASST segmentation was used to identify aberrant
genomic regions. Here we considered at least 5 probes
for each segment. The data discussed in this publication
have been deposited in NCBI’s Gene Expression Omni-
bus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/
accession number GSE22965).
Multiplex Ligation-Dependent Probe Amplification (MLPA)
MLPA was used to confirm copy number gains and
losses found within the selected candidate genes by SNP
array. MLPA probes were designed using NCBI Build
36.1. We used two probes for TCRA and one probe for
POU5F1, ANKS1B, FAM86D and PRKG1.P r o b e
sequences can be obtained upon request. MLPA was
performed as described previously [21]. Sample series of
SNP array (Table 1) and in addition to that DNA from
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using SoftGenetics GeneMarker version 1.70. We set 1.2
and 0.8 as a threshold to detect the gains and losses
respectively.
Expression Array and Data Analysis
In total, we analyzed 7 ECs while 2 growth plate and 4
articular cartilage samples served as a control (Table 1).
Expression array was performed using Illumina Human-
6 v3.0 Expression BeadChips (Illumina Inc., San Diego,
CA). For Illumina BeadArray assay, cRNA was synthe-
sized with an Illumina RNA Amplification Kit (Ambion,
Austin, TX, USA), purified, labeled and hybridized as
per the manufacturer’s instructions. Then, arrays were
scanned with Illumina BeadArray reader (500GX, Illu-
mina) and scanned images were imported in BeadStudio
software version 3.1.3.0 (Illumina). For the expression
array, unprocessed data were collected from BeadStudio
and processed using VST [22] and quantile normaliza-
tion with the R bead array package [23]. The processed
data was analyzed using Linear Models for Microarray
Data (LIMMA) analysis which uses moderated t-test to
detect differentially expressed genes between two groups
by taking into account natural variance within these
groups and correcting for multiple testing using false
discovery rate [24].
Real-time quantitative Reverse Transcriptase PCR
(qRT-PCR)
qRT-PCR was used to confirm the results obtained by
the integration of SNP and expression array. Here we
have used 5 controls (2 growth plates and 3 articular
cartilage) and 8 ECs (Table 1). RNA used for expres-
sion array was also used for the qRT-PCR. cDNA was
synthesized using 1 μg of total RNA with AMV reverse
transcriptase (Roche Applied Science, Almere, The
Netherlands) in combination with oligo-dT and ran-
dom hexamer priming and qPCR was performed as
described elsewhere [25]. Primer details can be pro-
vided upon request. Expression of the genes of interest
(FAM86D, POU5F1 and ANKS1B)w a sn o r m a l i z e db y
geometric averaging of multiple internal control genes
using the geNorm program [26]. Out of four normali-
zation genes the best three were selected within this
program: GPR108, SRPR and TBP. Relative quantifica-
tion was performed using standard curves, followed by
adjustment with the normalization factor calculated by
geNorm program [25]. The average relative expression
of gene of interest in ECs was compared to controls.
To see the EC specific gene expression changes, rela-
tive expression of ECs with change in copy number
was compared with ECs without change in copy
number.
Tissue Microarray (TMA)
Five TMA blocks were constructed using TMA master
(Zeiss, 3D Histech, Hungary) and each block contain
maximum 70 cores including seven control tissues
(growth plate, articular cartilage, breast carcinoma, pros-
tate, colon, skin and tonsil) for orientation purpose. In
total 5 TMA blocks contain 86 tumors, of which 65
Ollier related and 21 solitary ECs and CS (Table S1,
Additional file 1). The TMA blocks contain 2-mm cores
of each tumor in triplicate.
Immunohistochemistry
Tissue sections were cut from TMA blocks and dried
overnight at 60˚C. Slides were kept in Xylol for 20 min-
utes. Immunohistochemistry was performed as described
earlier [27]. Detailed information on the antibodies used
to check protein expression of POU5F1 and NIPBL are
given in table S2, additional file 1. We used power
vision (poly-HRP-GAM/R/R, Immunologic) as a second-
ary antibody. Visualization was carried out with liquid
Dab
+ substrate chromogen system (DAKO, Glostrup,
Denmark). As a negative control primary antibody was
omitted. Immunostained TMA slides were scanned
using a high resolution Mirax Desk instrument (Zeiss,
Mirax 3D Histech, Hungary) and scored independently
by two observers (JVMGB and TCP) with the Mirax
viewer TMA module software version 1.1.12 (Zeiss) and
discrepancies were discussed. In brief, the intensity
(0 = no staining, 1 = weak, 2 = moderate, 3 = strong)
and percentage of positive tumors cells (0 = 0%, 1 =
1-24%, 2 = 25-49%, 3 = 50-74%, 4 = 75-100%) were
assessed. Cores with a negative internal control and loss
of tissue were excluded from the analysis. A sum score
≥ 4 was considered positive. Statistical analysis was done
using Pearson Chi-Square test in SPSS (version 16.0,
Chicago, Illinois, USA).
Results
Genome-wide detection of copy number alterations and
loss of heterozygosity using SNP array
Samples L1975, L1974, L1980, L813, L1083 and L286N
were excluded from further analysis because of quality
issues and low call rates. All samples including 29 con-
trols and 32 tumors (14 ECs, 18CS) showed DNA copy
number aberrations mainly restricted to known variable
regions (Figure 1)[28,29]. CNA were more frequently
found in CS II and CS III as compared to ECs and CS I
(Figure 1). The number of copy number changes in sal-
iva and blood DNA were comparable.
Genetic alterations in Ollier Enchondromas
We used paired analysis which is based on the compari-
son of tumor and corresponding normal DNA (available
for 5 ECs from 4 patients) to study LOH and CNA.
Pansuriya et al. Orphanet Journal of Rare Diseases 2011, 6:2
http://www.ojrd.com/content/6/1/2
Page 4 of 11Figure 1 Genome-wide copy number alterations in all 22 chromosomes. A) Copy number alterations in controls, Ollier enchondromas (ECs)
and chondrosarcoma (CS) grade I, II, III. The upper panel shows genome-wide frequency plots of gains and losses in 29 controls and 32 Ollier
tumors. Gains are plotted in green above 0% baseline and losses are plotted in red below 0% baseline. The X-axis corresponds to the genomic
region from chromosomes 1 to 22 and the Y-axis represents the percentage of gains and losses of all selected samples at the specific location in
genome. The lower panel shows frequency plot of 29 controls, 14 ECs, 12 CS I, 4 CS II and 2 CS III. The number and size of genomic alterations
increases with increasing tumor grade. Enchondromas and control samples show a comparable number and size of genomic alterations, which can
be attributed to common copy number variation. B) An example of copy number alterations in Ollier enchondroma (L206). This figure shows copy
number alterations in all 22 chromosomes of enchondroma (L206). The black band indicates the number of copies of the chromosomes. The blue
bands show the unpaired LAIR value. The lower band of this contains the originally uninformative homozygous SNPs. The top band indicates
heterozygous informative SNPs. With LOH or imbalances between the alleles, the position of this band will decrease. As a loss of chromosome 6
these heterozygous SNPs are becoming homozygous showing the LOH. C) An example of copy number alterations in Ollier chondrosarcoma grade
III (L810). Copy number loss with LOH is present at chromosome 4, 5q, 6q, 9p, 12p, 13 and 14q.
Pansuriya et al. Orphanet Journal of Rare Diseases 2011, 6:2
http://www.ojrd.com/content/6/1/2
Page 5 of 11Although sequences of homozygous SNPs were identi-
fied that could indicate LOH, these same sequences
were also observed in the corresponding normal sample.
We could not find any LOH in these 5 ECs using both
R and Nexus softwares. We have identified 7 EC specific
CNA by paired approach (Table 2). Selection of candi-
date genes TCRA, ANKS1B and PRKG1 for further vali-
dation is based on copy number change in minimum 10
probes within the gene.
Unpaired analysis revealed absence of LOH in the
majority of ECs. We confirmed the loss of chromo-
some 6 with LOH in L206 (Figure 1B) which was in
agreement with the results published previously by our
group using array CGH [30] proving validity of the
assay. Also loss of one copy of chromosome 3 and 6
with LOH was found in L1683. These results were con-
firmed using R and Nexus software. Furthermore, an
unpaired approach (29 contro l sa sab a s e l i n e )w a su s e d
to find most common copy number gains and losses in
at least 5 out of 14 ECs (Table S3, Additional file 1)
using Nexus. None of these were confirmed in paired
comparison which suggests that they are not tumor
specific changes. When ECs are located in the phalan-
geal bones, cellularity is increased [1]; we could not
find differences between ECs or CSI of the hand versus
those of long bones at the genomic level although the
sample sizes are small.
Homozygous deletion of FAM86D at chromosome
3p12.3 was found in two ECs in one patient (L206 and
L910) and selected for further validation (Figure 2).
Interestingly both ECs were located in different digits of
the hand. It was not possible to get normal DNA from
the same patient to investigate tumor specific loss of
FAM86D.
Genetic alterations in Ollier chondrosarcomas
Ollier CS showed large genomic alterations and LOH at
various locations in the genome (Table 3, Figure 1C).
Frequent recurrent CNA involves chromosomes 3p, 5q,
6q and 9p.
Verification of gene copy number alterations by MLPA
To validate regions identified by SNP arrays, we per-
formed MLPA on 37 Ollier tumors (Table 1) and 38
controls for the candidate genes FAM86D, TCRA,
ANKS1B and PRKG1 (Table 4). In addition, a probe was
designed at POUF51 which is at chromosome 6p21.31
in order to confirm loss of chromosome 6 in L206 and
L1683. We have used 38 controls as a baseline. Results
of validation experiments are summarized in Table 4.
In short we confirmed three (FAM86D, PRKG1 and
monosomy 6) out of five candidate regions. We con-
firmed the homozygous loss of FAM86D in two ECs of
t h es a m ep a t i e n t( F i g u r e2 ) .G a i na tPRKG1 in L1490 is
confirmed which seems to be EC specific in this case
but was not found in other ECs and CS. Loss at chro-
mosome 6 using probe at POU5F1 was confirmed in
L206 while loss was not confirmed in L1683 at given
thresholds. TCRA region at chromosome 14q11.2 is
known as a highly polymorphic region [31] and its fre-
quent rearrangements are observed in blood lympho-
cytes [32]. We used majority of blood samples as a
baseline and found copy number gain in all ECs at
TCRA as a result of SNP array unpaired analysis. Paired
analysis with SNP array showed copy number gain at
TCRA in L1978 and was not confirmed with MLPA.
Indeed this gain was due to loss in the corresponding
normal DNA. Loss at ANKS1B in L2220 was not con-
firmed by MLPA at given thresholds however the peak
was lower in L2220 compared to corresponding normal.
Expression array and its integration with copy number
alterations
Expression array was performed using 7 ECs and 6 con-
trols with Illumina Human-6 v3.0 (Table 1). We per-
formed function based analysis by integrating the gene
expression results with SNP array results. In total 1044
genes were differentially expressed in ECs compared
to controls (adj. p-value < 0.01, Table S4, Additional
file 1). We considered all up regulated genes (881 genes,
adj. p-value < 0.01) with presence of gain in at least one
EC and all down regulated genes (163 genes, adj. p-value <
0.01) with presence of loss in at least two ECs. We found
NIPBL which was gained as well as up regulated while
POU5F1 that was lost as well as down regulated in ECs
compared to controls. The same pattern was found in CS.
Validation of integration approach of SNP and expression
array using qRT-PCR
Using qRT-PCR, we confirmed lower expression of
ANKS1B, FAM86D and POU5F1 (Table 4). L2220
showed one copy loss of ANKS1B and its expression
was decreased in this EC as compared to the average of
relative expression of other 7 ECs however there is no
Table 2 Paired copy number alterations in Ollier
enchondromas
Patient ID Sample Cytoband Copy number
event in EC
Region
29 L1978 14q11.2* gain TCRA
25 L2220 12q23.1* loss ANKS1B
25, 54 L2220, L1490 10q11.22 loss intergenic region
54 L1490 1p31.3 loss intergenic region
54 L1490 2q11.2 gain intron of VWA3B
54 L1490 5q13.2 loss intergenic region
54 L1490 10q11.23* gain intron of PRKG1
* Candidate regions selected for further validation based on minimum 10
affected probes within the gene.
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Page 6 of 11Figure 2 FAM86D. A) Homozygous loss of FAM86D in L206. A 200 Mb region containing the FAM86D gene at 3p12.3 is shown (X-axis). The
gene lies in a ~100 Mb homozygous deleted region, within a larger area of hemizygous deletion. The individual copy number probes are
shown as the log ratio of the intensity and zero is two copies. The horizontal lines are segments with identical copy number as identified by the
HMM SNP-FASST algorithm. B) MLPA for 38 controls, 14 Ollier enchondromas (ECs) and 23 Ollier chondrosarcomas (CS). The Y-axis shows ratio
profile and 1.0 indicates two copies of a given chromosomal locus. Homozygous copy loss of the FAM86D as shown by SNP array was
confirmed in L206 and L910. Most of the controls and tumors show either two copies or hemizygous loss of this gene. Note that only outliers
are displayed with ID numbers.
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controls. SNP array results revealed homozygous loss in
L206, L910 and one copy loss in L2103 for FAM86D.
FAM86D expression was decreased in ECs compared to
controls. There was no expression of POU5F1.
Protein expression
Using a TMA we demonstrated that POU5F1 protein
expression was absent in all Ollier tumors which is in
line with the expression array and qRT-PCR results. For
NIPBL, 30% of Ollier tumors were positive (Figure 3,
Table 4). Only 34/65 Ollier and 11/21 solitary tumors
could be analyzed since cores from the rest of the
tumors were lost during the immunohistochemistry.
There was no significant difference in the expression of
NIPBL within the tumors of different grades in Ollier
disease (Pearson Chi-Square, p-value = 0.1).
Discussion
The origin of both solitary and Ollier related ECs is lar-
gely unknown. To address this, we performed genome-
wide analysis of ECs occurring in non-hereditary Ollier
disease. Since these tumors are polyostotic, with a uni-
lateral predominance, manifesting early in life, we postu-
lated that there may be a germ-line mosaicism. We
attempted to find causative genes for ECs of the Ollier
disease using a high-resolution SNP array containing 1.8
million markers combined with expression array and
obtained comprehensive genetic profiles of 37 Ollier dis-
ease related tumors. This is the first and largest genome-
wide molecular study on Ollier disease reported so far,
which was possible through the collaboration of many
different institutes within the EuroBoNeT Network and
the European Musculo-Skeletal Oncology Society
(EMSOS).
Table 3 Genetic alterations in Ollier chondrosarcomas
Sample Tumor Grade Gain Loss LOH Copy neutral LOH
L2218 CS I - - - -
L204 CS I 1q 3p,4q 3p,4q -
L253 CS I 1q 6p,6q,9p,12q,13 6p,6q,9p,12q,13 -
L1977 CS I - - - -
L1685 CS I - 2q 2q -
L1687 CS I 3p,7q,8q - - -
L2386 CS I - 6p,11q - -
L2103b CS I - - - -
L2221 CS I 14q,17q - - -
L1513 CS I - - - -
L2280 CS I - - - -
L2513 CS I - - - -
L286 CS II 5p,11p,11q,18p 3p,5p,5q,6q,9p,11p,18p,18q 3p,5p,6q,9p,11p,18p,18q -
L1976 CS II 8q - 8q -
L2098 CS II 2,5,7,15,16,17q,18,20,21 10,17q 10,17q 11
L2099 CS II - - - -
L810 CS III - 4,5q,6q,9p,12p,13,14q 4,5q,6q,9p,12p,13,14q -
L2104a CS III 1q,2p,2q,12p,14q 3q,5q,7q,9p,12p, 22 3q,5q,7q,9p,12p,22 2q
Some of the regions with loss do not show loss of heterozygosity (LOH). This could be explained by the loss of alleles in an aneuploid background.
Table 4 Summary of validation experiments for the candidate genes
Candidate
genes
Technique used Summary of validation
PRKG1 MLPA No copy number change in controls. Gain in tumor (1/37)
FAM86D MLPA, qRT-PCR Loss in controls (5/38), gain in controls (1/38), HMloss in tumors (2/37) loss in tumours (6/37). Lower m-RNA
expression in ECs
POU5F1 MLPA, qRT-PCR,
IHC
Gain in controls (3/38), loss in tumors (4/37), gain in tumors (2/37). Its mRNA and protein expression was absent
in tumors
ANKS1B MLPA, qRT-PCR No copy number changes in controls and tumors. Lower m-RNA expression in L2220 compared with other
7ECs
TCRA _probe1 MLPA Loss in controls (4/38), gain in tumors (2/37)
TCRA _probe2 MLPA Loss in controls (4/38), gain in tumors (2/37)
NIPBL IHC 30% Ollier tumors showed protein expression
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absence of large genetic aberrations in Ollier ECs except
loss of chromosome 6 in two ECs from two unrelated
Ollier patients. Small non-recurrent genetic changes
combining the SNP and expression array at FAM86D,
PRKG1, ANKS1B, NIPBL and POUF51 were found in
ECs. Most of these genes are not known to play an
important role in cartilage formation. We found homo-
zygous loss of FAM86D in two ECs of the same patient.
Function of FAM86D is still unknown. We confirmed
intronic gain at PRKG1 in one EC, which is involved in
fatty acid metabolism [33]. We found loss at ANKS1B,
while overexpression of ANKS1B is reported in pre-B
cell acute lymphocytic leukaemia [34]. Gain at NIPBL
was found in L2205 while at the protein level only 30%
of Ollier ECs and CS expressed NIPBL. Inactivating
mutations in NIPBL are associated with Cornelia de
Lange syndrome and one of the characteristic features
of this syndrome is reduction in limb growth (OMIM
122470). Loss of POU5F1 was found in two ECs with
monosomy at chromosome 6 and its mRNA and protein
expression was absent in all Ollier and solitary ECs and
CS. The transcription factor POU5F1 (OCT3/4) is
involved in regulating pluripotency and is normally
expressed during early embryogenesis in embryonic
stem and germ cells [35].
Here we studied extensively candidate genes obtained
from paired analysis of enchondromas. Normal DNA
was available from 4 Ollier patients enabling paired ana-
lysis. Despite the low number of paired samples our
data suggest that no common CNA are associated with
EC development. Extending the analysis with the
unpaired samples we could not see any common CNA
in all ECs. All aberrations we obtained in at least 5 out
of 14 ECs are reported as common copy number var-
iants in DGV database (http://projects.tcag.ca/variation/).
Loss of chromosome 6 was the only recurrent change in
ECs of two unrelated Ollier patients. Therefore, relatively
small numbers of copy number alterations that we found
p e rE C sa r em o r el i k e l yt ob es e c o n d a r yr a n d o mg e n e t i c
changes. Although SNP array technology is a powerful
analysis tool, it can not detect balanced chromosomal
translocations, inversions and whole-genome ploidy
changes. However, balanced translocations and inver-
sions have not been reported for the Ollier tumors in the
literature so far [2].
Previously, PTH1R was reported to be the gene caus-
ing Ollier disease [6]. However, in subsequent studies it
was shown that PTH1R is only mutated in a sub group
of patients (~10%) decreasing receptor function to
~70%, suggesting that it may contribute to the disease
but is probably not causative [7]. PTH1R is a key player
within the IHH pathway which is crucial for endochon-
dral ossification. The presence of known point muta-
tions (R150C, R255H, G121E and A122T) in PTH1R
was excluded in the present series (unpublished data).
Also, we could not find a deletion or LOH at the
3p21.31 region harboring the PTH1R gene. Recently,
inactivating mutations in PTPN11 are reported in
another enchondromatosis subtype called metachondro-
matosis in which multiple ECs are combined with osteo-
chondroma-like lesions [2,36]. In our series we could
not detect any CNA or LOH at PTPN11 by SNP array.
Also, expression of PTPN11 was not decreased in ECs
as compared to controls in expression array.
Large gains, losses and LOH were seen more often in
Ollier CS as compared to ECs, which is in line with
increased genetic instability and aneuploidy seen in soli-
tary central chondrosarcoma progression. Most common
CNA involve 3p, 5q, 6q and 9p in Ollier CS. However,
we could not detect recurrent CNA in all Ollier CS that
could have been responsible for malignant transforma-
tion of ECs. For Ollier CS, a deletion at the short arm
of chromosome 1 [37], LOH at RB1 at chromosome 13
a n dp 1 5 / p 1 6l o c ia tt h es h o r ta r mo fc h r o m o s o m e9
[38] were reported in single cases each. Our results
show very few copy number alterations in ECs and an
increased number of variable genomic alterations in CS.
This is in support of the multistep model for CS devel-
opment [39].
In conclusion, we present genome-wide copy number
and expression profiles of the largest international series
of Ollier ECs and CS reported so far. We show absence
of recurrent CNA and LOH in majority of ECs suggest-
ing that instead point mutations or other copy number
neutral structural changes (inversions, insertions,
balanced translocations) or deletions below the resolu-
tion of this platform involving a single or a few exons
only [40] might have an important role in EC pathogen-
esis. This opens the possibility to study these tumors
further using a next generation sequencing approach.
An increased number of genetic alterations are found in
Ollier CS, supporting the multistep genetic progression
model.
Figure 3 NIPBL protein expression. A) Example of nuclear
expression of NIPBL in Ollier enchondroma (400 times magnification).
B) Number of Ollier and solitary tumors with nuclear NIPBL
expression.
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Additional file 1: Table S1, Table S2, Table S3, Table S4. Table S1 -
Clinicopathological data of 86 tumors used in TMA - * Gender
information was not available for four Ollier patients. Table S2 - Antibody
information Table S3 - Unpaired copy number changes in 35% of EC
(min. 5 out of 14) - All the copy number gains and losses that we found
in more than four ECs are an indicative of known copy number variation
in DGV database of genomic variants. Table S4 - List of up and down
regulated genes in enchondromas compared to controls using
expression array (adj. p-value < 0.001)
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